DrugPatentWatch Database Preview➤ Subscribe for complete access
« Back to Dashboard
Summary for Patent: 7,208,162
|Title:||Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents|
|Abstract:||Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibodies, and an additional anti-inflammatory agent, especially corticosteroids, as well as anti-inflammatory antibodies, especially anti-interleukin-6. Also disclosed are methods of using such compositions to treat and/or prevent respiratory diseases. Such compositions may optionally contain other non-antibody anti-viral agents.|
|Inventor(s):||Prince; Gregory (Potomac, MD), Johnson; Leslie S. (Germantown, MD)|
|Assignee:||MedImmune, Inc. (Gaithersburg, MD) Virion Systems, Inc. (Rockville, MD)|
|Patent Claims:||1. A method of treating respiratory syncytial virus infection (RSV) in a patient afflicted therewith comprising administering to said patient a therapeutically effective
regimen of an anti-RSV antibody and a steroid wherein said regimen is administered systemically.
2. The method of claim 1 wherein the steroid is a corticosteroid.
3. The method of claim 2 wherein said corticosteroid is selected from the group consisting of cortisone, hydrocortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, beclamethasone and dexamethasone.
4. The method of claim 1 wherein the anti-viral antibody is administered in a dosage of 5 to 20 mg/kg body weight.
5. The method of claim 1 wherein the anti-viral antibody is MEDI-493 (palivizumab).
6. The method of claim 1 wherein said steroid is administered in the dosage range is 0.5 mg to 50 mg per kg body weight.
7. The method of claim 1 wherein said steroid is administered in a dosage of 10 .mu.g to 1 gram per kg body weight.
8. The method of claim 1 wherein said antibody and said steroid are administered contemporaneously.
9. The method of claim 1 wherein the antibody is administered prior to administering the steroid.
10. The method of claim 1 wherein the steroid is administered prior to administering the antibody.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Approval Date||Patent No.||Expiredate|
|Swedish Orphan Biovitrum Ab (publ)||SYNAGIS||palivizumab||For Injection||103770||1998-06-19||⤷ Sign up for a Free Trial||2020-05-03|
|Swedish Orphan Biovitrum Ab (publ)||SYNAGIS||palivizumab||Injection||103770||2004-07-23||⤷ Sign up for a Free Trial||2020-05-03|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Approval Date||>Patent No.||>Expiredate|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.